Related Experiment Video
Updated: Jan 21, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Adverse-Event Free Survival, Hospitalizations, and Mortality in Left Ventricular Assist Device Recipients: A
Windy Alonso1, Judith E Hupcey, Lisa Kitko
1Windy Alonso, PhD, RN Doctoral Student, The Pennsylvania State University, College of Nursing, Hershey. Judith E. Hupcey, EdD, CRNP, FAAN Associate Dean for Research and Professor, Nursing and Medicine, The Pennsylvania State University, College of Nursing, Hershey. Lisa Kitko, PhD, RN, FAHA, FAAN Associate Professor, The Pennsylvania State University, College of Nursing, University Park. Bunny Pozehl, PhD, APRN-NP, FHFSA, FAHA, FAAN Professor and Dorothy Hodges Olson Endowed Chair, University of Nebraska Medical Center, College of Nursing, Omaha. Kevin Kupzyk, PhD Assistant Professor, University of Nebraska Medical Center, College of Nursing, Omaha.
Background:
The number of individuals with advanced heart failure (HF) receiving left ventricular assist devices (LVADs) is growing. Postimplantation LVAD recipients return home to both rural and urban locations. The impact of rural or urban living on postimplantation outcomes has not been adequately explored.
Objective:
This cohort study examined adverse event-free survival, hospitalization-free survival, and all-cause mortality between rural and urban LVAD recipients in the first 2 years after implantation.
Methods:
Data from LVAD recipients (N = 141) implanted at a single center in the northeastern United States were analyzed. Recipients of LVAD were designated as rural or urban by county of residence. Adverse events, hospitalizations, and survival time were examined using multivariate Cox proportional hazards models.
Results:
Thirty-seven percent of LVAD recipients in the cohort were rural. Two-thirds of all LVAD recipients experienced at least 1 adverse event (96/141, 68.1%). Although more urban recipients experienced adverse events, including death, rural versus urban models of both adverse events and survival were nonsignificant (adverse events: log-rank = 1.18, P = .28; hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.57-1.63; P = .89; survival: log-rank =2.81, P = .09; HR, 0.45; 95% CI, 0.17-1.23; P = .12). Rural LVAD recipients experienced significantly more hospitalizations and shorter hospitalization-free survival (log-rank = 6.67, P = .009). However, the HR for survival was nonsignificant (HR, 1.5; 95% CI, 0.94-2.39; P = .08).
Conclusions:
Frequent adverse events and hospitalizations are of ongoing concern for LVAD recipients. More data are necessary to understand why urban LVAD recipients may experience shorter survival time compared with rural counterparts. Hospitalization may serve as a protective factor for rural LVAD recipients.
Related Concept Videos
Hospitals-II
Nurses that work in...
Hospitals-I
Survival Tree
Building a Survival Tree
Constructing a...
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
The Sense of Self: Reflected Self-Appraisal and Social Comparison

